Trial · NCT07085806
To Study Effect of Injection Pentoxifylline on Liver Growth After Major Liver Surgery
NCT07085806, Not applicable, Recruiting, Institute of Liver and Biliary Sciences, India
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. To Study Effect of Injection Pentoxifylline on Liver Growth After Major Liver Surgery. Trials, record NCT07085806. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07085806
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- To Study Effect of Injection Pentoxifylline on Liver Growth After Major Liver Surgery
- NCT number
- NCT07085806
- Status
- Recruiting
- Phases
- Not applicable
- Enrollment
- 60 participants, estimated
- Lead sponsor
- Institute of Liver and Biliary Sciences, India
- Conditions
- Liver Regeneration
- Interventions
- Pentoxifylline (also known as oxpentifylline), Plasmalyte
- First posted
- 2025-07-25
- Last updated
- 2025-07-25
Source ClinicalTrials.gov
Registered outcomes13
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | To assess effect of Pentoxifylline supplementation on Anatomical (Volume) Regeneration of liver in the Perioperative period (POD-14) in Right lobe donor Hepatectomy | 2 weeks post-operatively | Regenerated liver volume post-surgery Day-14 and Percentage of volume restored after Post surgery day 14 as compared to pre-operatively calculated Remnaant liver volume |
| Secondary | To evaluate the effect of Pentoxifylline on Serum Bilirubin- Time to Normalization | 2 weeks | Serum bilirubin on Post-operative Day 1 to 7 and 14 |
| Secondary | To evaluate the effect on HGF | 1 week | HGF (Hepatocyte Growth Factor) levels on Baseline, Postoperative Day 3, and Day 7 |
| Secondary | To study the effect of Pentoxifylline supplementation on post-operative complications in donor right hepatectomy | Postoperative Day 14 | Clavien-Dindo Classification Grading on Post-operative Day 14 |
| Secondary | Time to normalziation of Aspartate Transaminase | Post-operative Day 14 | Aspartate transaminase (Baseline, Post-operative Day 1 to 7 and 14) |
| Secondary | Time to normalzation of Alanine transaminase | Post-operative Day 14 | Alanine Transaminase on BASELINE, POST-OPERATIVE DAY 1 TO 7 and 14 |
| Secondary | Time to Normalisation of International Normalized Ratio | Post-operative Day 14 | International Normalized Ratio on Baseline Post-operative Day 1 to 7 and 14 |
| Secondary | Time to normalisation of Serum Alkaline phosphatase | Post-operative Day 14 | Serum Alkaline Phosphatase levels on Baseline, Post-operative Day 1 to 7 and 14 |
| Secondary | Time to normalisation of Gamma-Glutamyl Transferase | Post-operative Day 14 | Gamma-Glutamyl Transferase levels on baseline, Post-operative Day 1 to 7 and 14 |
| Secondary | Effect on TNF-alpha (Tumor Necrosis Factor alpha) | Post-operative Day 7 | TNF-alpha (Tumor Necrosis Factor alpha) levels on Baseline, Post-operative Day 3 and 7 |
1 to 10 of 13Source ClinicalTrials.gov
See all 13 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers3
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07085806
GET https://conductscience.org/api/trials/v1/NCT07085806/registered